U.S. ARKRAY’s Announces FDA Clearance of the Fully Automated Integrated Urine Analyzer AUTION HYBRID™ AU-4050

EDINA, Minn., Feb. 28, 2013 /PRNewswire/ -- U.S. ARKRAY Inc. announced today the FDA clearance of the Fully Automated Integrated Urine Analyzer AUTION HYBRID AU-4050. This latest addition to the U.S. ARKRAY Inc. urinalysis portfolio combines the proven ARKRAY urinalysis strip technology with fluorescent flow cytometry sediment analysis in one space-efficient unit (32"x 28") The attractive, compact size of the AUTION HYBRID AU-4050 does not compromise performance that laboratories of all sizes demand. The AUTION HYBRID AU-4050 improves sample throughput capabilities with continuous sample loading averaging a rate of 150 samples per hour. The full reflex testing capabilities allows laboratories to complete urine analysis on the same platform with minimal interaction.

(Photo: http://photos.prnewswire.com/prnh/20130228/CG68330)

"We are very excited to introduce the newest generation of the AUTION urinalysis instruments to the U.S. Market. With the introduction of the AUTION HYBRID AU-4050, U.S. ARKRAY Inc. is now ready to offer full automation of urine chemistry and sediment analysis to all laboratories where the complete automation of urinalysis is critical. The compact instrument size provides an extra benefit to any laboratory where space comes at a premium," said Susumu Akatsu, General Manager of U.S. ARKRAY Inc.

For details and commercial availability, please visit U.S. ARKRAY Inc. at www.arkraylab.com

U.S. ARKRAY is a wholly owned subsidiary of ARKRAY, Inc. of Kyoto, Japan. ARKRAY, Inc. was founded in 1960 as Kyoto Daiichi Kagaku Inc. (KDK) with a focus on medical diagnostic products. ARKRAY Inc. offers a broad in vitro diagnostic portfolio for the clinical laboratory. ARKRAY Inc. introduced the first automated urine analyzer in 1972. U.S. ARKRAY Inc. is constantly evaluating the clinical laboratory's needs and is committed to providing cost efficient solutions to the clinical laboratory. ARKRAY Inc. supports an R&D team of over 200 researchers and is dedicated to the advancement of medical science through innovation.

SOURCE U.S. ARKRAY, Inc.